<?xml version="1.0" encoding="UTF-8"?>
<p>With antiviral drugs, the scientific questions that need to be answered before the pandemic are not as daunting (
 <xref ref-type="bibr" rid="R13">
  <italic>13</italic>
 </xref>). Originally, both classes of antiviral drugs were believed to be effective against a pandemic virus. Adamantane action is limited to type A viruses, but all pandemic viruses are type A (
 <xref ref-type="bibr" rid="R15">
  <italic>15</italic>
 </xref>). The neuraminidases of many different type A viruses have been evaluated with respect to NAIs, and all have been found susceptible (
 <xref ref-type="bibr" rid="R1">
  <italic>1</italic>
 </xref>). As a result, given advance planning so that supplies are available, antiviral drugs can be used early in a pandemic and do not require specific production and formulation. Because they are much less costly than NAIs, adamantanes were part of the overall antiviral strategy (
 <xref ref-type="bibr" rid="R20">
  <italic>20</italic>
 </xref>). Having 2 classes of drug increased the amount of antiviral drugs available to stockpile since production limitations are an issue with the NAIs.
</p>
